PubMed:29787732 JSONTXT

{"project":"Zierdiyeerkenaili_800_3","denotations":[{"id":"T1","span":{"begin":41,"end":56},"obj":"CI"},{"id":"T10","span":{"begin":1211,"end":1216},"obj":"CI"},{"id":"T11","span":{"begin":1341,"end":1346},"obj":"CI"},{"id":"T12","span":{"begin":1490,"end":1495},"obj":"CI"},{"id":"T13","span":{"begin":1509,"end":1514},"obj":"CI"},{"id":"T14","span":{"begin":1636,"end":1641},"obj":"CI"},{"id":"T15","span":{"begin":1651,"end":1656},"obj":"CI"},{"id":"T16","span":{"begin":1692,"end":1697},"obj":"CI"},{"id":"T17","span":{"begin":209,"end":224},"obj":"CI"},{"id":"T18","span":{"begin":242,"end":255},"obj":"CI"},{"id":"T19","span":{"begin":503,"end":516},"obj":"CI"},{"id":"T2","span":{"begin":57,"end":70},"obj":"CI"},{"id":"T20","span":{"begin":810,"end":823},"obj":"CI"},{"id":"T21","span":{"begin":1024,"end":1037},"obj":"CI"},{"id":"T22","span":{"begin":1217,"end":1230},"obj":"CI"},{"id":"T23","span":{"begin":1515,"end":1528},"obj":"CI"},{"id":"T24","span":{"begin":1657,"end":1670},"obj":"CI"},{"id":"T25","span":{"begin":1698,"end":1711},"obj":"CI"},{"id":"T26","span":{"begin":110,"end":135},"obj":"DP"},{"id":"T27","span":{"begin":284,"end":309},"obj":"DP"},{"id":"T28","span":{"begin":1843,"end":1868},"obj":"DP"},{"id":"T3","span":{"begin":226,"end":231},"obj":"CI"},{"id":"T4","span":{"begin":492,"end":497},"obj":"CI"},{"id":"T5","span":{"begin":523,"end":528},"obj":"CI"},{"id":"T6","span":{"begin":804,"end":809},"obj":"CI"},{"id":"T7","span":{"begin":833,"end":838},"obj":"CI"},{"id":"T8","span":{"begin":1018,"end":1023},"obj":"CI"},{"id":"T9","span":{"begin":1087,"end":1092},"obj":"CI"},{"id":"T29","span":{"begin":538,"end":545},"obj":"CI"},{"id":"T30","span":{"begin":344,"end":351},"obj":"CI"},{"id":"T31","span":{"begin":848,"end":855},"obj":"CI"},{"id":"T32","span":{"begin":1056,"end":1063},"obj":"CI"},{"id":"T33","span":{"begin":1241,"end":1248},"obj":"CI"},{"id":"T34","span":{"begin":1473,"end":1480},"obj":"CI"},{"id":"T35","span":{"begin":1619,"end":1626},"obj":"CI"}],"text":"Randomized, Controlled, Phase 2 Trial of Povidone-Iodine/Dexamethasone Ophthalmic Suspension for Treatment of Adenoviral Conjunctivitis.\nPURPOSE: To evaluate the efficacy/safety of an ophthalmic suspension of povidone-iodine (PVP-I) 0.6% and dexamethasone 0.1% in patients with acute adenoviral conjunctivitis.\nDESIGN: Multicenter, randomized, vehicle-controlled, double-masked trial.\nMETHODS: Adults with a positive Rapid Pathogen Screening Adeno-Detector Plus test were randomized 1:1:1 to PVP-I 0.6%/dexamethasone 0.1%, PVP-I 0.6%, or vehicle, bilaterally 4 times daily for 5 days (days 1-5). Patients were evaluated on days 3, 6, and 12 (+1-day window). Efficacy measures included clinical resolution and adenoviral eradication.\nRESULTS: Overall, 144 patients were included in the efficacy analysis (PVP-I/dexamethasone, n = 48; PVP-I, n = 50; vehicle, n = 46). The proportion of patients with clinical resolution (primary study eye with last observation carried forward [LOCF]) at the day 6 visit was higher with PVP-I/dexamethasone (31.3%) than with vehicle (10.9%; P = .0158) and PVP-I (18.0%; P = nonsignificant). The proportion with adenoviral eradication (primary study eye with LOCF) was higher with PVP-I/dexamethasone than with vehicle at the day 3 (35.4% vs 8.7%; P = .0019) and day 6 (79.2% vs 56.5%; P = .0186) visits and vs PVP-I (day 3 visit, 32.0%; day 6 visit, 62.0%; each P = nonsignificant). Treatment-emergent adverse events (AEs) occurred in 69.0% (vehicle), 62.7% (PVP-I), and 53.4% (PVP-I/dexamethasone) of patients in the safety dataset. Discontinuation owing to AEs occurred in 37 patients (vehicle, n = 16; PVP-I, n = 12; PVP-I/dexamethasone, n = 9).\nCONCLUSION: PVP-I/dexamethasone appeared safe and well tolerated, and significantly improved clinical resolution and adenoviral eradication in patients with acute adenoviral conjunctivitis."}

{"project":"yaoziqian_800_3","denotations":[{"id":"T14","span":{"begin":1843,"end":1868},"obj":"DP"},{"id":"T15","span":{"begin":41,"end":56},"obj":"CI"},{"id":"T16","span":{"begin":57,"end":70},"obj":"CI"},{"id":"T17","span":{"begin":226,"end":231},"obj":"CI"},{"id":"T18","span":{"begin":492,"end":497},"obj":"CI"},{"id":"T19","span":{"begin":804,"end":809},"obj":"CI"},{"id":"T2","span":{"begin":110,"end":135},"obj":"DP"},{"id":"T20","span":{"begin":833,"end":838},"obj":"CI"},{"id":"T21","span":{"begin":1018,"end":1023},"obj":"CI"},{"id":"T22","span":{"begin":1087,"end":1092},"obj":"CI"},{"id":"T23","span":{"begin":1211,"end":1216},"obj":"CI"},{"id":"T24","span":{"begin":1341,"end":1346},"obj":"CI"},{"id":"T25","span":{"begin":1490,"end":1495},"obj":"CI"},{"id":"T26","span":{"begin":1509,"end":1514},"obj":"CI"},{"id":"T27","span":{"begin":1636,"end":1641},"obj":"CI"},{"id":"T28","span":{"begin":1651,"end":1656},"obj":"CI"},{"id":"T29","span":{"begin":1692,"end":1697},"obj":"CI"},{"id":"T3","span":{"begin":209,"end":224},"obj":"CI"},{"id":"T30","span":{"begin":1698,"end":1711},"obj":"CI"},{"id":"T31","span":{"begin":810,"end":823},"obj":"CI"},{"id":"T32","span":{"begin":1024,"end":1037},"obj":"CI"},{"id":"T33","span":{"begin":1217,"end":1230},"obj":"CI"},{"id":"T34","span":{"begin":1515,"end":1528},"obj":"CI"},{"id":"T35","span":{"begin":1657,"end":1670},"obj":"CI"},{"id":"T36","span":{"begin":1619,"end":1626},"obj":"CI"},{"id":"T37","span":{"begin":344,"end":351},"obj":"CI"},{"id":"T38","span":{"begin":538,"end":545},"obj":"CI"},{"id":"T39","span":{"begin":848,"end":855},"obj":"CI"},{"id":"T4","span":{"begin":242,"end":255},"obj":"CI"},{"id":"T40","span":{"begin":1056,"end":1063},"obj":"CI"},{"id":"T41","span":{"begin":1241,"end":1248},"obj":"CI"},{"id":"T42","span":{"begin":1473,"end":1480},"obj":"CI"},{"id":"T5","span":{"begin":284,"end":309},"obj":"DP"},{"id":"T7","span":{"begin":503,"end":516},"obj":"CI"},{"id":"T8","span":{"begin":523,"end":528},"obj":"CI"}],"text":"Randomized, Controlled, Phase 2 Trial of Povidone-Iodine/Dexamethasone Ophthalmic Suspension for Treatment of Adenoviral Conjunctivitis.\nPURPOSE: To evaluate the efficacy/safety of an ophthalmic suspension of povidone-iodine (PVP-I) 0.6% and dexamethasone 0.1% in patients with acute adenoviral conjunctivitis.\nDESIGN: Multicenter, randomized, vehicle-controlled, double-masked trial.\nMETHODS: Adults with a positive Rapid Pathogen Screening Adeno-Detector Plus test were randomized 1:1:1 to PVP-I 0.6%/dexamethasone 0.1%, PVP-I 0.6%, or vehicle, bilaterally 4 times daily for 5 days (days 1-5). Patients were evaluated on days 3, 6, and 12 (+1-day window). Efficacy measures included clinical resolution and adenoviral eradication.\nRESULTS: Overall, 144 patients were included in the efficacy analysis (PVP-I/dexamethasone, n = 48; PVP-I, n = 50; vehicle, n = 46). The proportion of patients with clinical resolution (primary study eye with last observation carried forward [LOCF]) at the day 6 visit was higher with PVP-I/dexamethasone (31.3%) than with vehicle (10.9%; P = .0158) and PVP-I (18.0%; P = nonsignificant). The proportion with adenoviral eradication (primary study eye with LOCF) was higher with PVP-I/dexamethasone than with vehicle at the day 3 (35.4% vs 8.7%; P = .0019) and day 6 (79.2% vs 56.5%; P = .0186) visits and vs PVP-I (day 3 visit, 32.0%; day 6 visit, 62.0%; each P = nonsignificant). Treatment-emergent adverse events (AEs) occurred in 69.0% (vehicle), 62.7% (PVP-I), and 53.4% (PVP-I/dexamethasone) of patients in the safety dataset. Discontinuation owing to AEs occurred in 37 patients (vehicle, n = 16; PVP-I, n = 12; PVP-I/dexamethasone, n = 9).\nCONCLUSION: PVP-I/dexamethasone appeared safe and well tolerated, and significantly improved clinical resolution and adenoviral eradication in patients with acute adenoviral conjunctivitis."}